Equities analysts expect that Cellectis SA (NASDAQ:CLLS) will announce $9.43 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Cellectis’ earnings, with the highest sales estimate coming in at $10.69 million and the lowest estimate coming in at $7.60 million. Cellectis reported sales of $8.96 million during the same quarter last year, which indicates a positive year over year growth rate of 5.2%. The firm is expected to report its next quarterly earnings report on Wednesday, August 1st.
According to Zacks, analysts expect that Cellectis will report full-year sales of $36.10 million for the current fiscal year, with estimates ranging from $31.30 million to $41.98 million. For the next fiscal year, analysts expect that the firm will report sales of $47.77 million per share, with estimates ranging from $32.00 million to $77.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Cellectis.
Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, May 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.01). Cellectis had a negative return on equity of 37.45% and a negative net margin of 337.45%. The firm had revenue of $8.07 million for the quarter, compared to the consensus estimate of $9.53 million.
Several equities analysts have weighed in on CLLS shares. Zacks Investment Research cut shares of Cellectis from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. BidaskClub upgraded shares of Cellectis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 17th. Nomura lifted their price objective on shares of Cellectis to $73.00 and gave the stock a “buy” rating in a research report on Wednesday, March 14th. Guggenheim started coverage on shares of Cellectis in a research report on Friday, March 16th. They set a “neutral” rating on the stock. Finally, ValuEngine upgraded shares of Cellectis from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Cellectis has an average rating of “Hold” and an average price target of $42.00.
Large investors have recently modified their holdings of the business. Perceptive Advisors LLC bought a new position in Cellectis during the fourth quarter valued at about $10,203,000. Nexthera Capital LP purchased a new stake in Cellectis in the first quarter valued at $10,485,000. BlackRock Inc. purchased a new stake in Cellectis in the fourth quarter valued at $4,422,000. Millennium Management LLC raised its position in Cellectis by 1,356.2% in the fourth quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock valued at $3,040,000 after purchasing an additional 97,128 shares during the period. Finally, Bain Capital Public Equity Management LLC purchased a new stake in Cellectis in the fourth quarter valued at $2,848,000. 16.76% of the stock is owned by institutional investors.
NASDAQ CLLS opened at $29.95 on Wednesday. Cellectis has a twelve month low of $21.25 and a twelve month high of $38.85. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -10.77 and a beta of 1.88.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.